Bristol Myers Squibb at ACT 2026
Nov 15–18, 2026 San Antonio, TX ~1.4k attendees Website
Bristol Myers Squibb takes part in 5 sessions at ACT 2026 in San Antonio. Its program centres on carrying nonclinical safety findings into the clinic, from kidney safety signals to matching study-data terms with clinical ones. It also covers the draft ICH Q3E guideline on extractables and leachables, reuse of shared historical toxicology data, and career paths for toxicologists.
| Organization | ACT 2026 Attendance |
|---|---|
Global pharmaceutical company with marketed medicines in oncology, immunology, cardiovascular disease and neuroscience. | Talk Mon Nov 16 2:05pm–2:40pm Poster Mon Nov 16 5:00pm–6:30pm Poster Mon Nov 16 5:00pm–6:30pm Talk Tue Nov 17 2:05pm–2:40pm Session Wed Nov 18 2:00pm–3:15pm The Versatile Toxicologist: How to Leverage Expertise into Opportunity (S16)
|
Instantly find 20 buyers from Bristol Myers Squibb
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the American College of Toxicology (ACT). Organization details are derived from ACT’s published program, exhibitor floor plan and supporter list, and each organization’s own website. Submit a correction